Literature DB >> 11686189

Achieving a safe and early discharge for patients with community-acquired pneumonia.

D C Rhew1, S R Weingarten.   

Abstract

The rationale for achieving an early discharge for patients with CAP is that reduced length of stay can result in lower costs. When hospital discharge is premature, however, use of resources after discharge from the hospital may increase. This situation could increase overall cost and worsen quality of care. The objective should be to achieve a safe and early discharge. Several studies have evaluated methods for achieving this goal. Key findings from these studies are as follows: When a patient achieves clinical stability (e.g., systolic blood pressure, > or = 90 mm Hg; heart rate, < or = 100 beats/min; respiratory rate, < or = 24 breaths/min; temperature, < or = 38.3 degrees C [101 degrees F]; oxygen saturation, > or = 90%; able to eat; and stable mental status) or fulfills appropriate criteria (see Table 2), the patient may be eligible for switch from parenteral to oral antibiotics and early discharge. For many patients, this switch or discharge may occur on day 3 of hospitalization. When a patient is switched from parenteral to oral antibiotics, in many cases there does not appear to be a demonstrable clinical benefit to in-hospital observation. Elimination of in-hospital observation for patients who do not have an obvious reason for continued hospitalization potentially could reduce length of stay by 1 day. Improving efficiency of care reduces length of stay. This reduction may be accomplished by implementing clinical pathways, identifying and correcting causes of medically unnecessary hospital days, initiating early discharge planning, enlisting the services of a discharge coordinator, and organizing outpatient parenteral antibiotic treatment programs. These strategies are effective in many but not all patients, and their application should be tempered with careful clinical judgment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686189     DOI: 10.1016/s0025-7125(05)70389-8

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  6 in total

1.  Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Authors:  Brad Spellberg; Roger J Lewis; Helen W Boucher; Eric P Brass
Journal:  Clin Investig (Lond)       Date:  2011-01-01

2.  Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.

Authors:  Jan Jelrik Oosterheert; Marc J M Bonten; Margriet M E Schneider; Erik Buskens; Jan-Willem J Lammers; Willem M N Hustinx; Mark H H Kramer; Jan M Prins; Peter H Th J Slee; Karin Kaasjager; Andy I M Hoepelman
Journal:  BMJ       Date:  2006-11-07

Review 3.  Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Authors:  Brad Spellberg; George H Talbot; Eric P Brass; John S Bradley; Helen W Boucher; David N Gilbert
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

4.  Development of a risk prediction model of potentially avoidable readmission for patients hospitalised with community-acquired pneumonia: study protocol and population.

Authors:  Anne-Laure Mounayar; Patrice Francois; Patricia Pavese; Elodie Sellier; Jacques Gaillat; Boubou Camara; Bruno Degano; Mylène Maillet; Magali Bouisse; Xavier Courtois; José Labarère; Arnaud Seigneurin
Journal:  BMJ Open       Date:  2020-11-11       Impact factor: 2.692

5.  An Early Screening Tool for Discharge Planning Shortened Length of Hospital Stay for Elderly Patients with Community-Acquired Pneumonia.

Authors:  Hao Chen; Yu Hara; Nobuyuki Horita; Yusuke Saigusa; Takeshi Kaneko
Journal:  Clin Interv Aging       Date:  2021-03-10       Impact factor: 4.458

6.  An intervention program to reduce the number of hospitalizations of elderly patients in a primary care clinic.

Authors:  Roni Peleg; Yan Press; Maya Asher; Tatyana Pugachev; Hadas Glicensztain; Mila Lederman; Aya Biderman
Journal:  BMC Health Serv Res       Date:  2008-02-06       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.